Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 3 Study of Tasisulam vs Paclitaxel as Second-Line Treatment in Metastatic Melanoma
2009-014591-21Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tasisulam in melanoma (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: overall survival. Started Oct 2009; status: terminated.
02
Drugs
tasisulam
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-014591-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014591-21.